Last checked at 
LONDON (Alliance News) - Novacyt SA on Monday said its molecular testing division, Primerdesign Ltd, has expanded its assay development contract with Immunexpress Inc to further support the development of rapid diagnostic assays for the detection of sepsis.
Sepsis is a potentially life-threatening complication in which a person's immune system inappropriately responds to an infection by triggering a broader inflammatory response.
The AIM-listed diagnostics company said Primerdesign has been working in partnership with Immunexpress for over three years.
This expansion reaffirms Immunexpress' confidence in Primerdesign's development capabilities, Novacyt said, and highlights the division's pivotal role in assay development as it grows its relationships with global diagnostics companies.
"Our continued partnership with Novacyt supports our joint efforts to deliver multiplexed assays that improve the management and clinical outcomes of sepsis patients around the world," said Immunexpress Chief Executive Rolland Carlson.
"We aim to become the development partner of choice for molecular diagnostic companies who wish to efficiently deliver complex multiplexed assays," said Novacyt Chief Executive Graham Mullis.
Novacyt shares were trading 2.2% higher on Monday at 23.00 pence each.
